Can a new infusion stop the Body's attack on a transplanted kidney?

NCT ID NCT07764627

Not yet recruiting Disease control Sponsor: Hangzhou Sumgen Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests an experimental drug called SG301 in people who have antibody-mediated rejection after a kidney transplant. The goal is to see if the drug is safe and may help control the immune system's attack on the new kidney. Participants receive the drug by infusion weekly for a month, then every four weeks for about a year. The study focuses on safety and how well the drug works in this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SG301 injection, an experimental drug given by intravenous infusion
What this could lead to: If successful, this could offer a new treatment option to control antibody-mediated rejection and help preserve kidney function in transplant recipients.
What could go wrong: This is a small, early-phase trial with only 10 participants, so results may not apply broadly. The drug may cause side effects or fail to improve rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBODY MEDIATED REJECTION

Contacts and locations

Locations

Shulan(Hang Zhou) Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.